glp-1 microdosing research medications are changing how people think about weight loss, diabetes care and even cravings. Now, more people are talking about “microdosing” GLP-1s. That usually means taking less than the typical prescribed Microdosing GLP-1 Drugs: What To

Hypertension Elevated blood pressure that over time can cause the heart to work overtime and pump harder, possibly leading to heart attack, stroke, heart failure or kidney failure

You start at the lowest dose, move to the recommended dose after two weeks, and only increase further if weight loss is insufficient after 12 weeks

Similar trials are assessing GLP-1RAs in overweight patients with IBD (110), in UC (NCT06937086), and exploring dual GLP-1/GIP agonists like Zepbound as adjunctive therapies (NCT06774079) (112)

Currently, the BPC-157 peptide is not FDA-approved, and research is ongoing regarding its medical applications